VENU vs FBLG โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FBLG Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to FibroBiologics, Inc. Common Stock (FBLG) driven by superior Growth & Margin, Momentum & Technical while VENU counters with relative strength in Options & Structure. Fundamentally, VENU trades at N/M Forward P/E with -294.7% operating margin (+2.9% YoY revenue) versus FBLG at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VENU sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against FBLG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VENU | FBLG | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $58.3M | $7.5M | Larger Scale | VENU |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +2.9% | +0.0% | Higher Growth | VENU |
| Operating Margin (TTM) Profitability | -294.7% | 0.0% | Higher Margin | FBLG |
| Net Profit Margin Profitability | -281.4% | 0.0% | Higher Margin | FBLG |
| Return on Equity (ROE) Capital Efficiency | -24.9% | -1696.9% | Higher ROE | VENU |
| 52-Week Range Position Momentum | 1% ($1โ$11) | 14% ($0โ$4) | Stronger Trend | FBLG |
| Beta / 30D Volatility Risk Regime | 1.72ฮฒ ยท 86% Vol | -2.17ฮฒ ยท 68% Vol | Lower Realized Risk | FBLG |
| Unified Institutional Score Composite Signal | 42.3 / 100 (HOLD) | 41.0 / 100 (SELL) | Higher Composite | VENU |